ArticleHarm reduction journal2020
A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.
Article in Harm reduction journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Community trial evaluating the integration of Indigenous healing practices and a harm reduction approach with principles of seeking safety in an Indigenous residential treatment program in northern Ontario.BMC health services research · 2022Trial
- Trial
- Review
- Examining Integration of Comprehensive Substance Use Services in Certified Community Behavioral Health Clinics: A Cross-sectional Study.Administration and policy in mental health · 2026Article
- Family members' perspectives of laws, policies and practices in substance use disorders treatment: a qualitative exploration of seeking help for concurrent disorders.BMC psychiatry · 2026Article
- Strained patient-provider relationship, unmotivated workforce, financial constraints, and stigma: Multiple challenges in integrating mental health care within Vietnam's methadone clinics.Journal of ethnicity in substance abuse · 2025Article
- Cohort profile: the provincial opioid agonist treatment cohort in Ontario, Canada.European journal of epidemiology · 2025Article
- A tutorial on the what, why, and how of Bayesian analysis: Estimating mood and anxiety disorder prevalence using a Canadian data linkage study.PLOS mental health · 2025Article
- Observational
- Major Depression in Comorbidity with Substance use Disorders: Patients' Features and Clinical-Neurobiological Rationale of Antidepressant Treatments.Current neuropharmacology · 2025Review
- Observational
- Mental health and addiction concerns in northern Ontario: A cross-sectional study of sociodemographic predictors, access barriers, and service needs.PLOS mental health · 2025Article
- Certified Community Behavioral Health Clinic Services for Clients With Co-occurring Disorders: A Latent Class Approach.Psychiatric services (Washington, D.C.) · 2024Article
- Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway.Addiction science & clinical practice · 2024Article
- Association of hospital-based substance use supports on emergency department revisits: a retrospective cohort study in Sudbury, Canada from 2018 to 2022.Harm reduction journal · 2024Observational
- Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims.Drug and alcohol dependence reports · 2023Article
- Invited discussion on concurrent disorders.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2023Article
- Article
- Building an inpatient addiction medicine consult service in Sudbury, Canada: preliminary data and lessons learned in the era of COVID-19.Substance abuse treatment, prevention, and policy · 2023Observational
- The four-factor personality model and its qualitative correlates among opioid agonist therapy clients.Frontiers in psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to the high prevalence of mental disorders among people with opioid use disorder, the objective of this study was to determine the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment in Ontario, Canada.
methodsWe conducted a retrospective cohort study of patients enrolled in opioid agonist treatment between January 1, 2011, and December 31, 2015. Patients were stratified into two groups: those diagnosed with concurrent mental disorders and opioid use disorder and those with opioid use disorder only, using data from the Ontario Health Insurance Plan Database, Ontario Drug Benefit Plan Database. The primary outcome studied was all-cause mortality using data from the Registered Persons Database. Emergency department visits from the National Ambulatory Care Database, hospitalizations Discharge Abstract Database, and continuous retention in treatment, defined as 1 year of uninterrupted opioid agonist treatment using data from the Ontario Drug Benefit Plan Database were measured as secondary outcomes. Encrypted patient identifiers were used to link information across databases.
resultsWe identified 55,924 individuals enrolled in opioid agonist treatment, and 87% had a concurrent mental disorder diagnosis during this period. We observed that having a mental disorder was associated with an increased likelihood of all-cause mortality (odds ratio (OR) 1.4; 95% confidence interval (CI) 1.2-1.5). For patients diagnosed with mental disorders, the estimated rate of ED visits per year was 2.25 times higher and estimated rate of hospitalization per year was 1.67 times higher than for patients with no mental disorders. However, there was no association between having a diagnosis of a mental disorder and 1-year treatment retention in OAT-adjusted hazard ratio (HR) = 1.0; 95% CI 0.9 to 1.1.
conclusionOur findings highlight the consequences of the high prevalence of mental disorders for individuals with opioid use disorder in Ontario, Canada.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.